We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Mylan has not reached a settlement with the Justice Department to resolve allegations that it misclassified its allergy therapy the EpiPen for a Medicaid program, and as a result, underpaid state rebates, the Centers of Medicare and Medicaid said. Read More
Mallinckrodt will pay $100 million to settle FTC charges that the company maintained a U.S. monopoly for the only approved adrenocorticotropic hormone (ACTH) drug, Acthar, by acquiring the rights to a rival therapy, Synacthen. Read More
McKesson has agreed to pay a record civil penalty of $150 million to settle DEA and Justice Department allegations that the drug distributor failed to report suspicious orders of opioids. Read More
The high court will review Bristol-Myers Squibb’s appeal of a California Supreme Court ruling that grants the state’s courts jurisdiction to hear lawsuits filed by non-state residents. Read More
A majority of patent settlements reached last year in the European Union restricted the market entry of generics, according to a European Commission report. Read More
The Justice Department recovered $4.7 billion in False Claims Act settlements, with the largest recoveries coming from the life sciences industry at $1.2 billion in the last fiscal year. Read More
UK’s antitrust agency has accused Actavis of breaching competition law by raising the price of generic hydrocortisone tablets for Addison’s disease by more than 12,000 percent since 2008. Read More
Global drug spending will climb to $1.5 trillion in the next five years, marking a nearly 32 percent increase, fueled largely by new medicines and emerging markets. Read More
Six generics makers are facing a civil lawsuit for allegedly colluding to fix the prices of the antibiotic doxycycline hyclate and the diabetes drug glyburide. Read More